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NAMI-A is a ruthenium-based compound with selective anti-metastasis activity in experimental models of solid tumours. We
studied whether this activity was dependent on anti-angiogenic ability of NAMI-A. We thus investigated its in vitro effects on
endothelial cell functions necessary for angiogenesis to develop, as well as its in vivo effects in the chick embryo chorioallantoic
membrane model. Endothelial cell proliferation, chemotaxis, and secretion of the matrix-degrading enzyme metalloproteinase-
2 were inhibited by NAMI-A in a dose-dependent manner, and without morphologic signs of cell apoptosis or necrosis. Lastly,
NAMI-A displayed a dose-dependent in vivo anti-angiogenic activity in the chorioallantoic membrane model. These data
suggest that the anti-angiogenic activity of NAMI-A can contribute to its anti-metastatic efﬁcacy in mice bearing malignant solid
tumours.
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Ruthenium-based compounds have recently received an increased
attention as tools for investigating new anti-tumour agents
(Clarke and Stubbs, 1996; Sava et al, 1999a). Some of them have
reached an advanced milestone in the pre-clinical investigation
(Keppler et al, 1990; Sava et al, 1998a) and one, namely
imidazolium trans-imidazoledimethylsulfoxidetetrachlororuthenate
(NAMI-A) (Mestroni et al, 1998), is successfully completing a
phase I clinical trial at the Netherlands Cancer Institute of
Amsterdam (J Schellens, personal communication). The initial
evidences on the mode of action of NAMI-A, although far from
the clear elucidation, showed this compound free of direct cyto-
toxicity for tumour cells and of effects on primary tumour
growth (Sava et al, 1998a; Bergamo et al, 1999; Zorzet et al,
2000). Accumulated evidences indicated that NAMI-A inhibits
metastasis growth by a selective effect on the relationship between
metastatic cell and host environment, the importance of which for
cell survival is well documented (Gregoire and Lieubeau, 1995;
Nicolson and Menter, 1995; Radinsky, 1995). NAMI-A stimulated
ﬁbrosis growth at primary tumour site, with increased thickness of
tumour capsule, cohesion among tumour cells and reduced vascu-
lar invasion of tumor mass (Sava et al, 1998a). Importantly,
NAMI-A differs from most of the so-called anti-metastatic agents
in that it is not only active in preventing metastasis formation but
shows also good activity in inhibiting those already formed and in
advanced stage of growth, this effect being very likely responsible
for the increased survival time of the treated animals (Sava et al,
1999b). Since the metastasis occurrence is angiogenesis-dependent
(Carmeliet and Jain, 2000) we assessed the hypothesis that the
anti-metastasis activity of NAMI-A was correlated, at least partly,
with its anti-angiogenic properties.
MATERIALS AND METHODS
Compound and treatment
Imidazolium trans-imidazoledimethylsulfoxide tetrachlororuthe-
nate, ImH[trans-RuCl4(DMSO)Im] (NAMI-A), was prepared
according to already reported procedures (Mestroni et al, 1998),
and diluted stepwise from 240 mM to 5 mM with the culture
medium of endothelial cells.
Cell cultures
The human umbilical vein endothelial cells (HUVEC) were
prepared as described previously (Bussolino et al, 1992) and grown
in Petri dishes coated with 1% gelatin (Sigma Chemical Co, St
Louis, MO, USA) in M199 medium supplemented with 20% foetal
calf serum (FCS), 0.02% extract of bovine brain, and 0.01%
porcine heparin (both from Sigma). The human endothelial-like
immortalised cell line EA.hy926, derived from the fusion of
HUVEC with the lung carcinoma cell line A549 (Edgell et al,
1983) was maintained in Dulbecco’s modiﬁed Eagle’s medium
(DMEM) supplemented with 10% heat-inactivated FCS, 1% gluta-
mine, amphotericin B (2.5 mg ml
71), penicillin (100 U ml
71),
and streptomycin (50 mg ml
71). The neuroblastoma SK-N-BE
and ﬁbrosarcoma HT-1080 human cell lines were cultured in
DMEM supplemented with 10% FCS, 2 mM glutamine and penicil-
lin/streptomycin, 100 U ml
71 and 50 mg ml
71 respectively;
NIH3T3 mouse embryo ﬁbroblasts (American Type Culture Collec-
tion, ATCC, Rockville, MD, USA) were cultured in DMEM
supplemented with 10% FCS and 1% glutamine.
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The conditioned media (CM) of HUVEC, EA.hy 926, SK-N-BE,
HT-1080 and NIH3T3 cells were prepared by incubating sub-
conﬂuent cells in a T25 ﬂask with 6 ml of serum-free medium
(SFM) for 24 h. The supernatant was collected under sterile condi-
tions, centrifuged sequentially at 1200 and 12000 rpm for 10 min
to eliminate debris, and stored at 7208C.
Proliferation assay
HUVEC or EA.hy926 endothelial cells were plated in 96-well plates
(2.5610
3 cells well
71) in complete medium. After 24 h from seed-
ing (day 0) and on days 2 and 4, the medium was replaced (in
quadruplicate) with complete medium containing NAMI-A, with
complete medium alone (positive control), or with starvation
SFM (negative control). Cell number was estimated on day 6 by
the colorimetric method of Kueng et al (1989). Brieﬂy, cells were
ﬁxed for 15 min at room temperature with 2.5% glutaraldehyde,
stained for 20 min with 0.1% crystal violet in 20% methanol, solu-
bilised with 10% acetate, and read at 595 nm (Microplate Reader
3550, Bio-Rad Laboratories, Richmond, CA, USA). Cell number
was derived from a calibration curve set-up with a known number
of cells. NAMI-A effects upon endothelial cell proliferation were
evaluated also after treatment times shorter than 144 h (48 h,
72 h and 96 h), as well as in the same experimental conditions
used for chemotaxis and matrix metalloproteinase assays, i.e., after
24- and 18-h treatment times.
Chemotaxis assay
This was carried out by the Boyden chambers as described
previously (Vacca et al, 1999). HUVEC or EA.hy926 endothelial
cells, pre-treated for 24 h with NAMI-A, were treated with tryp-
sine (0.05%) and acetate (0.02%), collected by centrifugation,
re-suspended in DMEM supplemented with 0.1% bovine serum
albumin (BSA, Sigma Chemical Co), and seeded in triplicate in
the upper compartment of a Boyden chamber (1.2610
5 cells/
400 ml). The lower compartment was ﬁlled with 200 ml of the
NIH3T3 CM as chemo-attractant or with DMEM supplemented
with 0.1% BSA as negative control (to evaluate random migra-
tion). The two compartments were separated by a polycarbonate
ﬁlter (12 mm pore size, Nucleopore, Costar, Cambridge, MA,
USA) coated with 0.005% gelatine to allow cell adhesion. After
6-h incubation in humidiﬁed 5% CO2 air at 378C, cells on the
upper side of the ﬁlter were removed, whereas those which had
migrated to the lower side were ﬁxed in absolute ethanol, stained
with toluidine blue, and counted in 5 to 8 oil immersion ﬁelds at
4006.
MMP-2 sodium dodecylsulfate-polyacrylamide gel
electrophoresis (SDS–PAGE) activity
Effect on MMP-2 secretion by EA.hy926 cells T25 ﬂasks of
EA.hy926 cells at 80% conﬂuence were rinsed twice with serum-
free DMEM and incubated for 18 h in this medium either alone
(positive control) or in the presence of NAMI-A. Culture media
were collected, and the total protein content measured by the Brad-
ford method (Bio-Rad Laboratories), using BSA as standard. To
visualise the gelatinolytic activity of MMP-2 secreted in the CM,
20 mg aliquots of CM proteins were applied to 7.5% SDS–PAGE
co-polymerised with type A gelatine from porcine skin (Sigma
Chemical Co) at a ﬁnal concentration of 0.6 g l
71. After electro-
phoresis in dual laboratory system (Protean II, Bio-Rad
Laboratories), gels were washed in 2.5% Triton for 1 h to remove
SDS, incubated for 18 h at 378C, and then stained with 0.1%
Coomassie brilliant blue. The gelatinolytic regions were observed
as white bands against a blue background. MMP activity was
measured by scoring the intensity of bands by computerised image
analysis (APPLE, Computer Inc, Cupertino, CA, USA).
Chick embryo chorioallantoic membrane (CAM) assay and
quantiﬁcation of the angiogenic response
Fertilized White Leghorn chicken eggs (20/group) were incubated
under constant humidity at 378C. On the third day of incubation,
a square window was opened in the shell after removal of 2–3 ml
of albumen so as to detach the developing CAM from the shell.
The window was sealed with a glass of the same dimension, and
the eggs were returned to the incubator. On day 8, 1 mm
3 steri-
lized gelatin sponges (Gelfoam, Upjohn Co, Kalamazoo, MI,
USA) loaded with 3 ml of PBS (negative control), or containing
1.0 mg per sponge of recombinant ﬁbroblast growth factor-2
(FGF-2, R&D System, Abingdon, UK) alone (positive control) or
together with NAMI-A (120 mM and 240 mM, dissolved in 2 ml
PBS) were implanted on top of the CAM. CAMs were examined
daily until day 12 and photographed in ovo with a Zeiss SR stereo-
microscope equipped with the MC63 Camera System (Zeiss,
Oberkochen, Germany). Blood vessels entering the sponge within
the focal plane of the CAM were counted by two observers in a
double-blind fashion at 506. At day 12, CAMs were processed
for light microscopy. Brieﬂy, the embryos and their membranes
were ﬁxed in ovo in Bouin’s ﬂuid, dehydrated in graded ethanols,
embedded in parafﬁn, serially sectioned at 7 mm, according to a
plane perpendicular to their free surface, stained with a 0.5% tolui-
dine blue, and observed under a light microscope.
The angiogenic response was evaluated as microvessel density
in the CAM area under the implant. The area occupied by
microvessels was estimated by using a morphometric method
of ‘point counting’ (Ribatti et al, 1995). Brieﬂy, every third
section with 30 serial slides from an individual specimen was
analysed simultaneously by two investigators by a 144-intersec-
tion point-square reticulum of 0.125 mm
2 inserted in the
eyepiece of the double-head light microscope. Six randomly
chosen microscopic ﬁelds of each section were evaluated at
2506 for the total number of the intersection points that were
occupied by vessels transversally cut (diameter ranging from 3 to
10 mm). Mean values+standard deviation (s.d.) for vessel counts
were determined for each analysis. The vascular density was indi-
cated by the ﬁnal mean number of the occupied intersection
points, expressed as a percentage of the total number of intersec-
tion points.
RESULTS
Effect of NAMI-A on endothelial cells
To evaluate the effects of NAMI-A upon endothelial cell prolifera-
tion, HUVEC or EA.hy926 cells were exposed on days 0, 2 and 4 to
complete medium (positive control), or to this medium admixed
with different NAMI-A concentrations, or to the starvation SFM
(negative control), and their proliferation rate was measured on
day 6 by a colorimetric method. NAMI-A induced a dose-depen-
dent inhibitory effect on endothelial cell proliferation (Figure 1).
In the concentration range between 5 and 80 mM, endothelial cells
were not able to proliferate as controls although maintaining their
viability, thus indicating that NAMI-A produced a cytostatic effect.
In contrast, the cell number at 120 mM was signiﬁcantly lower than
the number of cells cultured in the SFM, thus indicating that
NAMI-A induced cell death. Signs of cytotoxicity, namely vacuoli-
sation, nuclear fragmentation and homogenisation, cellular
shrinking or membrane blebbing, loss of elongated shape and cell
detachment were indeed detected at 120 mM.
Both HUVEC and EA.hy926 cells, pre-treated for 24 h with
different concentrations of NAMI-A and left to migrate towards
the NIH3T3 CM chemo-attractant in the Boyden chambers,
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which rose 50% of the positive control at 40 mM (Figure 2).
Lastly, EA.hy926 cells were exposed to increasing concentrations
of NAMI-A for 18 h, and their CM were tested for the presence
and activity of MMP-2 by gelatin zymography and gelatinolysis
scoring. Unexposed cells gave MMP-2 gelatinolytic band with an
apparent relative molecular mass of 62 kDa (Figure 3A), indicating
that the enzyme was constitutively secreted and readily activated
(Van Wart and Birkedal-Hansen, 1990). In this form, MMP-2
persisted in CM even after exposure to NAMI-A, but its secretion
declined signiﬁcantly at 20 mM and further at 40 mM (Figure 3B).
Importantly, inhibition of chemotaxis and MMP-2 production
occurred without inhibition of endothelial cell proliferation. Cell
number after 18- and 24-h NAMI-A treatment (40, 120 and
240 mM) was not statistically different from controls (data not
shown).
Effect of NAMI-A on angiogenesis in vivo
The CAMs (20 per series) were examined macroscopically on the
incubation day 12. CAMs implanted with the angiogenic factor
FGF-2 (positive control) displayed a vasoproliferative response in
form of allantoic vessels spreading radially towards the sponge in
a spoked wheel pattern (Table 1 and Figure 4A). When the sponge
was loaded with PBS, physiologic angiogenesis was observed as
fewer allantoic vessels arranged partly around the sponge and
partly converging towards it (Table 1). By contrast, very few vessels
were detectable with 120 mM and even fewer with 240 of mM
NAMI-A (Table 1 and Figure 4B).
Histologic examination and planimetric vessel counting were
also performed (Table 2). FGF-2-loaded sponges displayed a dense
collagenous matrix and numerous blood vessels among the sponge
trabeculae (Table 2 and Figure 4C). By contrast, very few or no
vessels could be detected inside the PBS- and NAMI-A-loaded
sponges (Table 2 and Figure 4D).
DISCUSSION
NAMI-A was repeatedly described to inhibit lung metastasis
growth of solid metastasising murine tumours (Sava et al, 1998a,
1999b; Zorzet et al, 2000) by a mechanism unrelated to tumour cell
direct cytotoxicity (Sava et al, 1998a; Bergamo et al, 1999).
Here we show NAMI-A to inhibit a number of in vitro endothe-
lial cell functions, namely proliferation, chemotaxis and matrix
metalloproteinase production. These functions are essential steps
for neovessel sprouting (Kubota et al, 1988; Connolly et al, 1989)
and angiogenesis, which is an important biological process involved
in metastasis formation (Liotta et al, 1991; Weidner et al, 1991).
Importantly, throughout the experiment with the CAM model, this
study showed NAMI-A to prevent in vivo angiogenesis at doses
known to have anti-metastasis activity. In fact, NAMI-A concentra-
tion in the lung of mice bearing pulmonary metastases, following a
treatment cycle (35 mg kg day
71 for six consecutive days) active
on metastasis growth, is in the range 100–300 mM (Sava et al,
1998b, 1999b; Cocchietto and Sava, 2000).
In vitro inhibitory effects of NAMI-A on endothelial cell func-
tions are dose-dependent and are obtained at non-cytotoxic
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Figure 1 Effect of NAMI-A upon endothelial cell proliferation. Low den-
sity cultures of endothelial cells (2.5610
3 well
71) were exposed on day 0,
2 and 4 with complete medium (positive control), serum-free medium
(negative control) or complete medium containing different NAMI-A con-
centrations. Cell number was evaluated on day 6 by Kueng et al’s method
(1989). Bars, means+s.d. of three independent experiments. *P50.05 and
**P50.01, Student–Newman–Keuls analysis of variance.
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Figure 2 Effect of NAMI-A upon endothelial cell chemotaxis.
1.2610
5 cells, exposed for 24 h to each dose of NAMI-A, were seeded
in the upper compartment of the Boyden chamber, and the conditioned
medium of NIH3T3 cells was placed in the lower compartment as the
chemoattractant. Unexposed cells were used in the positive and negative
control, respectively, the latter being devoid of the chemoattractant. Cells
that migrated after 6 h incubation to the lower surface of the ﬁlter separ-
ating the compartments were counted. Bars, means+s.d. of the number of
migrated cells in ﬁve to eight 400x ﬁelds of three ﬁlters per specimen.
*P50.05 and **P50.01, Student–Newman–Keuls analysis of variance.
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NAMI-A on both HUVEC and EA.hy926 cell proliferation is about
10 mM, i.e. a concentration more than 10-fold lower than the cyto-
toxic one. Interestingly, the inhibition of endothelial cell
proliferation required a rather long exposure of 144 h. No such
effect occurred with shorter challenges (up to 96 h), and on other
cell types such as TS/A, MCF7, B16F10 and KB NAMI-A showed a
marginal cytostatic effect at mM concentrations whereas 10–
100 mM NAMI-A were completely devoid of cell toxicity (Fnd Call-
erio, data on ﬁle). Similarly, the inhibitory effects upon chemotaxis
and matrix metalloproteinase production occurred in the absence
of any inhibition of cell proliferation or of cytotoxicity, thus indi-
cating the absence of a general toxic effect on the treated cells and
suggesting a peculiar mode of action of NAMI-A which deserves
further investigation; studies by Pintus et al, at the Department
of Biochemical Sciences of the University of Sassari, Italy, seem
to conﬁrm this hypothesis, showing NAMI-A active on the MAPK
ERK1/2 pathway (G Pintus, personal communication to G Sava).
NAMI-A inhibits chemotaxis of endothelial cells and particularly
the FGF-2-induced chemotaxis, since the NIH3T3 CM applied as
chemoattractant contains FGF-2 as the prominent stimulatory
factor (Rusnati and Presta, 1996). It also inhibits the production
of MMP-2 by EA.hy926 cells. This effect appears unrelated to a
general reduction of protein synthesis, since NAMI-A never did
show such effect on the treated cells (Bergamo et al, 1999).
However, although the evaluation of the treated cells by ﬂow cyto-
metry or by the sulforhodamine B test often showed an increase of
cell proteins, the possibility of the selective inhibition of focal
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Figure 3 Effect of NAMI-A on MMP-2 production by EA.hy926 cells.
MMP-2 activity was evaluated from a densitometric scan of bands resulting
on a SDS/polyacrylamide/gelatin gel loaded with the conditioned medium
of untreated (positive control) or NAMI-A-treated EA.hy926 cells.
Table 1 Chick embryo CAM-sponge assay: macroscopic assessment of
vascular density on incubation day 12
No. of No. of vessels at the
Sponge loaded with specimens sponge–CAM boundary
FGF-2 20 38+5
NAMI-A 120 mM 20 11+6**
NAMI-A 240 mM 20 5+3**
PBS 20 9+3**
Macroscopic quantitation was assessed as the number of vessels at 506 at the
sponge–CAM boundary. *Results are expressed as the mean+1 s.d. **P50.001
vs FGF-2 by the Student’s t-test for unpaired data.
A B
C D
Figure 4 The CAM of a 12-day-old chick embryo incubated for 4 days
with a gelatin sponge loaded with (A), (C) the angiogenic ﬁbroblast growth
factor-2 (FGF-2) or with (B), (D) 240 mM of NAMI-A. Note in (A) numer-
ous blood vessels converging like spokes toward the sponge, whereas in
(B) there are very few vessels around the sponge or converging toward
it. (C) Histologic section of the sponge shows numerous vessels (arrows)
intermingled in a collagenous matrix among the trabeculae. (D) No vessels
are detectable. Original magniﬁcations: A, B,5 0 6; C, D, 4006.
Table 2 Chick embryo CAM-sponge assay: microvessel density on day
12 of incubation
No. of No. of microvessels
Sponges loaded with specimens inside the sponge
FGF-2 20 25+5
NAMI-A 120 mM 20 8+4**
NAMI-A 240 mM 20 3+1**
PBS 20 0**
*Results are expressed as the mean+1 s.d. **P50.01 vs FGF-2 by the Student’s
t-test for unpaired data.
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the degradation of type IV, V, VII and X collagens and ﬁbronectin
(Mullins and Rohrlich, 1983) which are constituents of both the
basement membrane and the interstitial stroma (Tryggvason et
al, 1987). This degradation facilitates the intrusion of endothelial
cells across such structures, an important step for neovessel sprout-
ing (Mullins and Rohrlich, 1983; Tryggvason et al, 1987) and
metastasis formation (Tryggvason et al, 1987; Mignatti and Rifkin,
1993). Also, previous results by this group showed the inhibition of
mRNAs for MMP-2, specularly to the increase of the mRNA for
TIMP-2, to be associated to enhanced deposition of extracellular
matrix within the tumour, increased thickness of the capsule
surrounding it and appearance of a more deﬁned wall around
tumour blood vessels (Sava et al, 1996); all these events were
matched to a marked reduction of the formation of spontaneous
metastases.
NAMI-A can directly inhibit the enzymatic activity of MMP-2
and MMP-9, as shown by the zymography performed with condi-
tioned medium of ﬁbrosarcoma (HT-1080) and neuroblastoma
(SK-N-BE) tumour cells (data not shown). From the experimental
data, the 50% inhibitory concentration of NAMI-A can be esti-
mated around 1–1.5 mM. This concentration is about 10-times
higher than that obtained in tumour masses after a complete cycle
of in vivo treatment, therefore a direct effect of NAMI-A upon
matrix metalloproteinase activity appears irrelevant.
Importantly, the concentrations of NAMI-A active in vitro on
endothelial cell functions, and effective in vivo in the CAM model,
are easily reached from the beginning of the schedule of anti-
metastasis treatment. In fact, considering that (i) 24 h after the
sixth injection, NAMI-A is about 0.2 mM in the lungs, the site of
metastasis growth, (ii) tissue distribution from the blood compart-
ment is rather fast immediately after injection (Sava et al, 1999b;
Cocchietto and Sava, 2000), and that (iii) the half-life time for
elimination after repeated treatments is about 20 h (Cocchietto
and Sava, 2000), ruthenium concentration in these tissues after
the ﬁrst injection is not less than one half of that found at the
end of treatment.
Therefore it may be supposed that the ﬁnding that ‘active’
concentrations may persist in vivo in the mouse lungs for up to
48 h after last drug injection should warrant the exposure of the
tumour cells present in these tissues for a time long enough to
induce effects on the metastatic cells even greater than those
presently observed in vitro.
In conclusion, this study demonstrates that NAMI-A can be
credited with anti-angiogenic activity, this property probably
contributing to its widely described in vivo anti-metastasis effect.
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